Lisa M McGregor
Overview
Explore the profile of Lisa M McGregor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
427
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caru M, Alberts N, Freeman M, Dandekar S, Rao P, McKeone D, et al.
Support Care Cancer
. 2023 Mar;
31(4):228.
PMID: 36952029
Background: Pain is one of the most common and distressing symptoms experienced by children and adolescents diagnosed with cancer. It is vital that children and adolescents receive adequate pain management...
2.
Santana V, Sahr N, Tatevossian R, Jia S, Campagne O, Sykes A, et al.
Cancer
. 2020 Jan;
126(8):1749-1757.
PMID: 31967673
Background: The prognosis for children with recurrent solid tumors generally is poor. Targeting mammalian target of rapamycin (mTOR) and vascular endothelial growth factor A with everolimus and bevacizumab, respectively, synergistically...
3.
Rao P, Segel J, McGregor L, Lengerich E, Drabick J, Miller B
J Adolesc Young Adult Oncol
. 2019 Oct;
9(1):47-54.
PMID: 31600095
Adolescents and young adults (AYAs) with cancer are a vulnerable population with decreased attendance at National Cancer Institute (NCI) comprehensive cancer centers and Children's Oncology Group (COG) facilities. Decreased attendance...
4.
Lam C, Furman W, Wang C, Spunt S, Wu J, Ivy P, et al.
J Pediatr Hematol Oncol
. 2014 Jun;
37(1):e13-8.
PMID: 24942022
Oxaliplatin, although related to cisplatin and carboplatin, has a more favorable toxicity profile and may offer advantages in combination regimens. We combined oxaliplatin, ifosfamide, and etoposide (IOE) and estimated the...
5.
Navid F, Sondel P, Barfield R, Shulkin B, Kaufman R, Allay J, et al.
J Clin Oncol
. 2014 Apr;
32(14):1445-52.
PMID: 24711551
Purpose: The addition of immunotherapy, including a combination of anti-GD2 monoclonal antibody (mAb), ch14.18, and cytokines, improves outcome for patients with high-risk neuroblastoma. However, this therapy is limited by ch14.18-related...
6.
Federico S, Allewelt H, Spunt S, Hudson M, Wu J, Billups C, et al.
J Pediatr Hematol Oncol
. 2014 Mar;
37(1):e6-e12.
PMID: 24633303
Background: Most prior studies evaluating subsequent malignant neoplasms (SMNs) in patients with neuroblastoma are restricted to long-term survivors and/or their treatment exposures. This study investigates SMNs in patients diagnosed with...
7.
Kieran K, Williams M, McGregor L, Dome J, Krasin M, Davidoff A
J Pediatr Surg
. 2014 Jan;
49(1):149-53.
PMID: 24439600
Background: Renal insufficiency is a significant complication of Wilms tumor treatment in the 5% with bilateral disease. Nephron-sparing surgery (NSS) is recommended after neoadjuvant chemotherapy initially. However, the role of...
8.
Kieran K, Williams M, Dome J, McGregor L, Krasin M, Davidoff A
J Pediatr Surg
. 2013 Jul;
48(7):1481-5.
PMID: 23895958
Purpose: Nephron-sparing surgery (NSS) has been advocated for patients with bilateral Wilms tumor (BWT). We sought to determine whether margin status impacted local tumor recurrence. Methods: A retrospective review of...
9.
Hartwich J, Orr W, Ng C, Spence Y, McLaughlin J, Furman W, et al.
J Pediatr Surg
. 2013 Jan;
48(1):47-55.
PMID: 23331792
Purpose: Osteoprotegerin (OPG) is a decoy receptor for the Receptor of NF-κB (RANK) ligand that can inhibit osteoclastogenesis. Previous studies have suggested that Mammalian Target of Rapamycin (mTOR) inhibition upregulates...
10.
Navid F, Baker S, McCarville M, Stewart C, Billups C, Wu J, et al.
Clin Cancer Res
. 2012 Nov;
19(1):236-46.
PMID: 23143218
Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and pharmacodynamics of sorafenib, bevacizumab, and low-dose oral cyclophosphamide in children and young adults with recurrent/refractory solid tumors. Experimental...